Previous 10 | Next 10 |
-- Data to be presented from in-practice clinician case series on novel immunomodulation strategy -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced multiple presentations that will highlight the serious, systemic effect of urate deposition and will inform strategies to optimiz...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced integrated, pooled efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab for the treatment of active thyroid eye disease (TED) compared to placebo. The results support prior analyses of significant reductions in infl...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it is has been named one of the Most Innovative Companies in Chicago by Crain’s Chicago Business , ranking number two. Crain’s compiles the list based on a review by independent intellectual property valuation fir...
New pooled data from the Phase 2 and Phase 3 clinical trials of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc (Nasdaq: HZNP), will be presented during an oral plenary presentation at the 89 th Annual Meeting of the American Thyroid Association (ATA) in...
Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been selected to FORTUNE Magazine’s 2019 “ Best Medium Workplaces ” list for the fourth consecutive year. Horizon ranked eighth out of 100 other medium sized companies. “We are honored that FOR...
Horizon Therapeutics (NASDAQ: HZNP ) has initiated PROspective sTudy of pEglotiCase in Transplant patients (PROTECT), an open-label trial evaluating the use of KRYSTEXXA (pegloticase injection) in 20 adults with chronic gout refractory to conventional therapies, also known a...
-- Trial to evaluate the effectiveness of KRYSTEXXA to sustain reduced serum uric acid levels for post-kidney transplant adults; a vulnerable population -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has initiated an open-label clinical trial evaluating the use of KRYSTE...
The FDA has a history of stepmotherly behaviour with Amarin (AMRN). We saw it between 2013 and 2015, when the FDA issued a CRL to Amarin when the company asked for a very reasonable label expansion - and the FDA took an entire year to even issue the CRL. The saga of those sordid years can be...
Horizon Therapeutics ( HZNP +3% ) reports new data from Phase 3 OPTIC confirmatory clinical trial that shows teprotumumab provided significant benefit on several effects of active thyroid eye disease -- such as double vision, quality of life, and clinical activity score -- vs. placebo. ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double visio...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...